Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 63Carcinoma, Hepatocellular 55Lung Neoplasms 32Breast Neoplasms 29Small Cell Lung Carcinoma 23Neoplasms 21Triple Negative Breast Neoplasms 18Neoplasm Metastasis 17Urinary Bladder Neoplasms 15Carcinoma, Transitional Cell 15Melanoma 14Colorectal Neoplasms 14Glioblastoma 10Prostatic Neoplasms 9Ovarian Neoplasms 9Head and Neck Neoplasms 9Recurrence 8Liver Neoplasms 8Endometrial Neoplasms 8Carcinoma, Renal Cell 8Mesothelioma, Malignant 7Uterine Cervical Neoplasms 6Sarcoma 6Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Rectal Neoplasms 5Kidney Neoplasms 5Gastrointestinal Neoplasms 5Carcinoma, Squamous Cell 5Pancreatic Neoplasms 4

Interventions

tislelizumab 1selinexor 1atezolizumab 1anlotinib 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Extensive Stage Lung Small Cell Cancer × atezolizumab × Clear all
NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
165 enrolled

Extensive Stage Lung Small Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡